Drug Profile
Research programme: anticancer therapeutics - AbbVie/Celera
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Celera Diagnostics
- Developer AbbVie; Celera Corporation
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer